BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin Y, Parco C, Karathanos A, Krieger T, Schulze V, Chernyak N, Icks A, Kelm M, Brockmeyer M, Wolff G. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ Open 2022;12:e048893. [PMID: 35210334 DOI: 10.1136/bmjopen-2021-048893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Patti G, Cavallari I, Cesaro A, Gragnano F, Riva L, Fimiani F, Cuccia C, Fresco C, Calabrò P, Leonardi S, Marcucci R, Rubboli A. Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology. Vascul Pharmacol 2022;148:107137. [PMID: 36464086 DOI: 10.1016/j.vph.2022.107137] [Reference Citation Analysis]
2 Biolo G, Vinci P, Mangogna A, Landolfo M, Schincariol P, Fiotti N, Mearelli F, Di Girolamo FG. Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1028355] [Reference Citation Analysis]
3 Goit R, Saddik SE, Dawood SN, Rabih AM, Niaj A, Raman A, Uprety M, Calero MJ, Villanueva MRB, Joshaghani N, Villa N, Badla O, Khan S. Bempedoic Acid’s Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.29891] [Reference Citation Analysis]